NanoVibronix, Inc. (NASDAQ:NAOV) Short Interest Down 17.4% in June

NanoVibronix, Inc. (NASDAQ:NAOV) was the target of a significant decline in short interest in June. As of June 15th, there was short interest totalling 34,700 shares, a decline of 17.4% from the May 31st total of 42,000 shares. Based on an average trading volume of 38,800 shares, the short-interest ratio is presently 0.9 days. Currently, 1.3% of the company’s stock are short sold.

Institutional Investors Weigh In On NanoVibronix

A hedge fund recently bought a new stake in NanoVibronix stock. Armistice Capital LLC acquired a new position in shares of NanoVibronix, Inc. (NASDAQ:NAOV) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 29,023 shares of the company’s stock, valued at approximately $57,000. Armistice Capital LLC owned about 1.75% of NanoVibronix at the end of the most recent quarter. Hedge funds and other institutional investors own 16.39% of the company’s stock.

NanoVibronix Stock Down 1.8 %

NASDAQ NAOV traded down $0.01 during trading hours on Friday, hitting $0.70. 46,189 shares of the company were exchanged, compared to its average volume of 33,041. The firm has a market cap of $1.95 million, a price-to-earnings ratio of -0.41 and a beta of 1.45. The company has a 50 day moving average of $0.76 and a two-hundred day moving average of $0.90. NanoVibronix has a 52-week low of $0.68 and a 52-week high of $4.23.

NanoVibronix (NASDAQ:NAOV) last issued its earnings results on Wednesday, May 15th. The company reported ($0.23) earnings per share for the quarter. NanoVibronix had a negative net margin of 112.35% and a negative return on equity of 95.96%. The firm had revenue of $0.92 million during the quarter.

NanoVibronix Company Profile

NanoVibronix, Inc, through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.